Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
An expert discusses ALKS 3831, a potential new treatment that demonstrated reduced weight gain in patients with schizophrenia compared to olanzapine.
There remains a need for new schizophrenia treatments, preferably medications that do not elicit side effects such as weight gain or hallucinations that can often lead to poor adherence rates.
Researchers are hopeful a new drug, ALKS 3831, could be the answer because the combination drug has shown promise in reducing weight gain as a side effect from olanzapine.
ALKS 3831 is an investigational, novel atypical antipsychotic earmarked for once-daily oral application for the 2 psychiatric disorders composed of samidorphan, a novel, new molecular entity, co-formulated with olanzapine, an established antipsychotic agent in a single bilayer tablet.
Recently, officials from Alkermes released data from the treatment, specifically targeting the weight gain profile in schizophrenia patients.
In an interview with HCPLive®, Adam Simmons, MPH, Director of Clinical Program Management, Alkermes, said if clinicians are able to reduce weight gain as a medication side effect they might have more success in creating treatment plans for patients.
Simmons explained how much of a focal point side effects is during research of potential schizophrenia treatments.
The once-daily treatment has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of Nov. 15, 2020